These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 26468525

  • 1. The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-II.
    Quinn LL, Williams LR, White C, Forrest C, Zuo J, Rowe M.
    J Virol; 2016 Jan 01; 90(1):356-67. PubMed ID: 26468525
    [Abstract] [Full Text] [Related]

  • 2. The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules.
    Keating S, Prince S, Jones M, Rowe M.
    J Virol; 2002 Aug 01; 76(16):8179-88. PubMed ID: 12134023
    [Abstract] [Full Text] [Related]

  • 3. The Epstein-Barr virus-encoded BILF1 protein modulates immune recognition of endogenously processed antigen by targeting major histocompatibility complex class I molecules trafficking on both the exocytic and endocytic pathways.
    Zuo J, Quinn LL, Tamblyn J, Thomas WA, Feederle R, Delecluse HJ, Hislop AD, Rowe M.
    J Virol; 2011 Feb 01; 85(4):1604-14. PubMed ID: 21123379
    [Abstract] [Full Text] [Related]

  • 4. The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation.
    Zuo J, Currin A, Griffin BD, Shannon-Lowe C, Thomas WA, Ressing ME, Wiertz EJ, Rowe M.
    PLoS Pathog; 2009 Jan 01; 5(1):e1000255. PubMed ID: 19119421
    [Abstract] [Full Text] [Related]

  • 5. Distinct Roles of Extracellular Domains in the Epstein-Barr Virus-Encoded BILF1 Receptor for Signaling and Major Histocompatibility Complex Class I Downregulation.
    Fares S, Spiess K, Olesen ETB, Zuo J, Jackson S, Kledal TN, Wills MR, Rosenkilde MM.
    mBio; 2019 Jan 15; 10(1):. PubMed ID: 30647152
    [Abstract] [Full Text] [Related]

  • 6. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.
    Croft NP, Shannon-Lowe C, Bell AI, Horst D, Kremmer E, Ressing ME, Wiertz EJ, Middeldorp JM, Rowe M, Rickinson AB, Hislop AD.
    PLoS Pathog; 2009 Jun 15; 5(6):e1000490. PubMed ID: 19557156
    [Abstract] [Full Text] [Related]

  • 7. Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.
    Quinn LL, Zuo J, Abbott RJ, Shannon-Lowe C, Tierney RJ, Hislop AD, Rowe M.
    PLoS Pathog; 2014 Aug 15; 10(8):e1004322. PubMed ID: 25144360
    [Abstract] [Full Text] [Related]

  • 8. Epstein-Barr virus evades CD4+ T cell responses in lytic cycle through BZLF1-mediated downregulation of CD74 and the cooperation of vBcl-2.
    Zuo J, Thomas WA, Haigh TA, Fitzsimmons L, Long HM, Hislop AD, Taylor GS, Rowe M.
    PLoS Pathog; 2011 Dec 15; 7(12):e1002455. PubMed ID: 22216005
    [Abstract] [Full Text] [Related]

  • 9. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
    Ressing ME, Horst D, Griffin BD, Tellam J, Zuo J, Khanna R, Rowe M, Wiertz EJ.
    Semin Cancer Biol; 2008 Dec 15; 18(6):397-408. PubMed ID: 18977445
    [Abstract] [Full Text] [Related]

  • 10. EBV BILF1 evolved to downregulate cell surface display of a wide range of HLA class I molecules through their cytoplasmic tail.
    Griffin BD, Gram AM, Mulder A, Van Leeuwen D, Claas FH, Wang F, Ressing ME, Wiertz E.
    J Immunol; 2013 Feb 15; 190(4):1672-84. PubMed ID: 23315076
    [Abstract] [Full Text] [Related]

  • 11. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.
    Albanese M, Tagawa T, Bouvet M, Maliqi L, Lutter D, Hoser J, Hastreiter M, Hayes M, Sugden B, Martin L, Moosmann A, Hammerschmidt W.
    Proc Natl Acad Sci U S A; 2016 Oct 18; 113(42):E6467-E6475. PubMed ID: 27698133
    [Abstract] [Full Text] [Related]

  • 12. Induction of the Lytic Cycle Sensitizes Epstein-Barr Virus-Infected B Cells to NK Cell Killing That Is Counteracted by Virus-Mediated NK Cell Evasion Mechanisms in the Late Lytic Cycle.
    Williams LR, Quinn LL, Rowe M, Zuo J.
    J Virol; 2016 Jan 15; 90(2):947-58. PubMed ID: 26537677
    [Abstract] [Full Text] [Related]

  • 13. Kaposi's sarcoma-associated herpesvirus-encoded viral IRF3 modulates major histocompatibility complex class II (MHC-II) antigen presentation through MHC-II transactivator-dependent and -independent mechanisms: implications for oncogenesis.
    Zuo J, Hislop AD, Leung CS, Sabbah S, Rowe M.
    J Virol; 2013 May 15; 87(10):5340-50. PubMed ID: 23449805
    [Abstract] [Full Text] [Related]

  • 14. Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection.
    Ressing ME, Keating SE, van Leeuwen D, Koppers-Lalic D, Pappworth IY, Wiertz EJ, Rowe M.
    J Immunol; 2005 Jun 01; 174(11):6829-38. PubMed ID: 15905524
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of heavy chain and beta2-microglobulin synthesis as a mechanism of major histocompatibility complex class I downregulation during Epstein-Barr virus replication.
    Guerreiro-Cacais AO, Uzunel M, Levitskaya J, Levitsky V.
    J Virol; 2007 Feb 01; 81(3):1390-400. PubMed ID: 17108039
    [Abstract] [Full Text] [Related]

  • 16. Kaposi's sarcoma-associated herpesvirus K3 and K5 ubiquitin E3 ligases have stage-specific immune evasion roles during lytic replication.
    Brulois K, Toth Z, Wong LY, Feng P, Gao SJ, Ensser A, Jung JU.
    J Virol; 2014 Aug 01; 88(16):9335-49. PubMed ID: 24899205
    [Abstract] [Full Text] [Related]

  • 17. Mutant Cellular AP-1 Proteins Promote Expression of a Subset of Epstein-Barr Virus Late Genes in the Absence of Lytic Viral DNA Replication.
    Lyons DE, Yu KP, Vander Heiden JA, Heston L, Dittmer DP, El-Guindy A, Miller G.
    J Virol; 2018 Oct 01; 92(19):. PubMed ID: 30021895
    [Abstract] [Full Text] [Related]

  • 18. Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy.
    Adhikary D, Behrends U, Boerschmann H, Pfünder A, Burdach S, Moosmann A, Witter K, Bornkamm GW, Mautner J.
    PLoS One; 2007 Jul 04; 2(7):e583. PubMed ID: 17611619
    [Abstract] [Full Text] [Related]

  • 19. A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus.
    Voisset C, Daskalogianni C, Contesse MA, Mazars A, Arbach H, Le Cann M, Soubigou F, Apcher S, Fåhraeus R, Blondel M.
    Dis Model Mech; 2014 Apr 04; 7(4):435-44. PubMed ID: 24558096
    [Abstract] [Full Text] [Related]

  • 20. Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion.
    Rowe M, Glaunsinger B, van Leeuwen D, Zuo J, Sweetman D, Ganem D, Middeldorp J, Wiertz EJ, Ressing ME.
    Proc Natl Acad Sci U S A; 2007 Feb 27; 104(9):3366-71. PubMed ID: 17360652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.